Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Graveel, Carrie R ^a   deGroot, Jack D ^a   Sigler, Robert E ^b   van de Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Research Essential Services LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; CYSTEINE; METHIONINE; SCATTER FACTOR RECEPTOR; THREONINE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; C57BL 6 MOUSE; CANCER GENETICS; CARCINOGENESIS; CELL TYPE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE MUTATION; GENE TARGETING; GERM LINE; HISTOPATHOLOGY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; MUTATION;

MUS;

ANIMALS; GERM-LINE MUTATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL;

EID: 78149421495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013586     Document Type: Article

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 235: 177-182.
2. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
3. Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3: 650-665.
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
5. Stoker M, Gherardi E, Perryman M, Gray J (1987) Scatter factor is a fibroblastderived modulator of epithelial cell mobility. Nature (London) 327: 239-242.
6. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C (1993) Scatter factor/ hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123: 223-235.
7. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251: 802-804.
8. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214.
9. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73.
10. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, et al. (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18: 2343-2350.
11. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, et al. (2003) C-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
12. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, et al. (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66: 283-289.
13. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, et al. (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025-1037.
14. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, et al. (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361.
15. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, et al. (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953.
16. Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, et al. (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48: 5339-5349.
17. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, et al. (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 5387-5393.
18. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, et al. (2008) C-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 283: 2675-2683.
19. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, et al. (2004) Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101: 17198-17203.
20. Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF (1998) Signaling requirements for oncogenic forms of the met tyrosine kinase receptor. Oncogene 17: 2691-2700.
21. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, et al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94: 11445-11450.
22. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, et al. (1998) The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 95: 14417-14422.
23. Harvey M, McArthur MJ, Montgomery CA, Jr., Bradley A, Donehower LA (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7: 938-943.
24. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, et al. (2009) Met Induces Diverse Breast Carcinomas in Mice and is Associated with Human Basal Breast Cancer. Proc Natl Acad Sci U S A 106: 12909-12914.
25. Ward J, Anver M, Mahler J, Devor-Henneman D, eds (2000) Pathology of mice commonly used in genetic engineering (C57BL/6; 129; B6, 129; and FVB/N). Ames, IA: Iowa State University Press. pp 161-179.
26. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
27. Nieto AI, Shyamala G, Galvez JJ, Thordarson G, Wakefield LM, et al. (2003) Persistent mammary hyperplasia in FVB/N mice. Comp Med 53: 433-438.
28. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82: 1513-1520.
29. Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259-2265.
30. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, et al. (2005) C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113: 678-682.
31. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
32. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, et al. (2008) C-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 265: 258-269.
33. Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, et al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20: 66-69.
34. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell 17: 77-88.